New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
12:25 EDTCOV, WMGI, SNN, SYK, NUVA, ARTC, ZMH, JNJ, GMEDAnother bidder may emerge for ArthroCare, says William Blair
William Blair says it would not be surprised to see another bidder emerge for ArthroCare (ARTC). The firm lists Johnson & Johnson (JNJ) and Stryker (SYK)) as the most likely to submit a competing bid to Smith & Nephew's (SNN), and notes Biomet, Zimmer (ZMH) and Covidien (COV) could also have interest in the company. Should the deal for ArthroCare close as currently contemplated, William Blair thinks peers Globus Medical (GMED), NuVasive (NUVA) and Wright Medical (WMGI) could be takeover targets.
Check below for free stories on ARTC;SNN;GMED;NUVA;WMGI;JNJ;SYK;COV;ZMH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
15:00 EDTWMGI, JNJWright Medical hip suit weakness would be buying opportunity, says Brean Capital
Subscribe for More Information
10:02 EDTSNNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:22 EDTSNNSmith & Nephew downgraded to Hold from Buy at Jefferies
August 31, 2014
14:04 EDTJNJWorldwide Business Research to hold a conference
Subscribe for More Information
13:59 EDTWMGIRW Baird to hold a conference
Subscribe for More Information
13:23 EDTSNNGoldman to hold a conference
Subscribe for More Information
August 28, 2014
17:42 EDTJNJJ&J begins sales process for its medical device unit Cordis, WSJ says
Subscribe for More Information
10:20 EDTGMEDGlobus Medical management to meet with Oppenheimer
Subscribe for More Information
07:05 EDTCOVCovidien acquires Sapheon, terms not disclosed
Covidien announced that it has acquired Sapheon, Inc., a privately-held developer of venous disease treatments. Financial terms of the transaction were not disclosed.
August 26, 2014
19:33 EDTCOVCovidien shareholder sues to block sale to Medtronic, Bloomberg reports
Subscribe for More Information
07:31 EDTNUVAWilliam Blair to hold a field trip
Subscribe for More Information
August 25, 2014
08:27 EDTJNJJanssen Affiliate Cilag acquires Covagen, terms not disclosed
Subscribe for More Information
07:03 EDTJNJVIVUS acquires patents from Janssen Pharmaceuticals
VIVUS (VVUS) announced the acquisition of a group of patents from Janssen Pharmaceuticals (JNJ) covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.
August 24, 2014
21:54 EDTNUVAPiper Jaffray to hold a bus tour
Subscribe for More Information
August 22, 2014
07:01 EDTCOVCovidien acquires Reverse Medical, terms not disclosed
Subscribe for More Information
August 21, 2014
05:42 EDTJNJIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
07:18 EDTCOVMedtronic shares have upside with or without deal, says Deutsche Bank
Deutsche Bank sees limited downside risk and significant upside potential for shares of Medtronic (MDT), with or without the pending Covidien (COV) acquisition. Deutsche says the Q1 results show improving trends and it keeps a Buy rating on Medtronic with an $85 price target.
August 19, 2014
10:13 EDTGMEDOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:28 EDTGMEDGlobus Medical initiated with a Buy at Gabelli
Subscribe for More Information
08:22 EDTCOVMedtronic: We will continue to pay significant US taxes following Covidien deal
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use